Protective effect of resveratrol against oxidative stress in cholestasis.
BACKGROUND
We investigated the protective role of resveratrol in rat liver injuries induced by chronic biliary obstruction.


METHODS
Secondary biliary cirrhosis was induced by bile duct ligation for 28 days. Swiss albino rats were divided into the three following groups: group 1: sham (n = 7); group 2: bile duct ligation (n = 7); group 3: bile duct ligation plus resveratrol (n = 7). Bile duct ligation plus resveratrol group received 10 mg/kg dose of resveratrol intraperitoneally daily for 28 days. Liver damage and cholestasis were determined by the biochemical and the pathologic examination.


RESULTS
The present data showed a decrease in both plasma bilirubin levels and aspartate aminotransferase and alanine aminotransferase levels in the resveratrol-treated rats, when compared with bile duct ligation group (P < 0.05). In the resveratrol-treated rats, tissue levels of malondialdehyde and nitric oxide were significantly lower than that of the bile duct ligation (P < 0.002). The levels of glutathione in resveratrol-treated rats were significantly higher than that in bile duct ligation group (P < 0.004). The levels of interleukin-1alpha, interleukin-6, and tumor necrosis factor-alpha in resveratrol group were significantly lower than that in bile duct ligation group (P < 0.004, P < 0.001, P < 0.001, respectively). Administration of resveratrol in the rats with biliary obstruction resulted in inhibition of ductular proliferation and lymphocytic inflammation.


CONCLUSIONS
The present study demonstrates that intraperitoneal administration of resveratrol in bile duct ligated rats maintained antioxidant defenses and reduces liver oxidative damage and ductular proliferation. This effect of resveratrol may be useful in the preservation of liver function in cholestasis.
Ara
Cengiz
C
Inonu University Turgut Ozal Medical Center, Department of General Surgery, Malatya, Turkey. cara@inonu.edu.tr
Kirimlioglu
Hale
H
Karabulut
Aysun Bay
AB
Coban
Sacit
S
Ay
Selma
S
Harputluoglu
Murat
M
Kirimlioglu
Vedat
V
Yilmaz
Sezai
S
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology*; D001219:Aspartate Aminotransferases / Q000097:blood; D002779:Cholestasis / Q000378:metabolism* / Q000473:pathology; D002908:Chronic Disease; D016207:Cytokines / Q000378:metabolism; D019610:Cytoprotection; D005978:Glutathione / Q000378:metabolism; D007274:Injections, Intraperitoneal; D008099:Liver / Q000378:metabolism / Q000473:pathology; D008105:Liver Cirrhosis, Biliary / Q000378:metabolism / Q000473:pathology; D008297:Male; D008315:Malondialdehyde / Q000037:antagonists & inhibitors; D009569:Nitric Oxide / Q000037:antagonists & inhibitors; D018384:Oxidative Stress / Q000187:drug effects*; D051381:Rats; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage / Q000494:pharmacology*
D000975:Antioxidants; D016207:Cytokines; D013267:Stilbenes; D009569:Nitric Oxide; D008315:Malondialdehyde; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D005978:Glutathione; D000077185:Resveratrol